As of June 12, 2018 our Privacy Policy has been updated. For individuals in the European Union, CIL uses cookies on this website. Please review the new privacy statement to see how. By continuing to use this website you agree to us using cookies in accordance with our privacy statement. Click here for the new privacy statement..OK

Corporate Overview

October 6, 2021 – Cambridge Isotope Laboratories, Inc. (CIL) Launches Stable Isotope-Labeled and Unlabeled TCA Cycle Multi-component Mixes

Tewksbury, MA - Cambridge Isotope Laboratories, Inc. (CIL) is pleased to announce the release of our new stable isotope-labeled and unlabeled TCA cycle mixes to aid in the analysis of TCA-associated compounds in metabolic studies. The TCA (tricarboxylic acid) cycle, also known as the Krebs or citric acid cycle, plays an essential role in central carbon and energy metabolism. The study of its intermediates, and its ancillary compounds, has proven pivotal in not only understanding their impact on metabolism but also in profiling their function in oncogenesis, inflammation, and other pathologies.

September 10, 2021 – Otsuka Group of Companies Celebrates 100th Anniversary with New Symbol and Tagline

Otsuka Group Companies (parent company of Cambridge Isotope Laboratories, Inc.) began to celebrate its 100th anniversary on Sept. 1, 2021. Under the umbrella of Otsuka Holdings Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director, CEO: Tatsuo Higuchi), the Otsuka group consists of 194 companies, including Otsuka Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Factory, Inc., and Taiho Pharmaceutical Co., Ltd. Representing the entire group, Cambridge Isotope Laboratories would like to convey its appreciation for the patronage and support that has facilitated this milestone.

August 31, 2021 – Cambridge Isotope Laboratories, Inc. Is Now Offering Cannabis Standards for MS-based Testing

CIL now offers solutions for testing the quality and safety of cannabis products with the launch of a variety of stable isotope-labeled and native standards of THC, CBD, and other cannabinoids to assist with testing needs.

July 7, 2021 – Cambridge Isotope Laboratories, Inc. Announces the First Commercially Available Quantum-Grade Gas, 12C Methane QG-alpha™, for High-Performance Nitrogen-Vacancy (NV) Center Diamonds 

Cambridge Isotope Laboratories, Inc. (CIL), part of the Otsuka Group and the world's leading producer of stable isotopes and stable isotope-labeled compounds, is proud to launch the first commercially available 12C-enriched methane-grade gas for quantum applications.

March 29, 2021 – Cambridge Isotope Laboratories, Inc. and Bruker Biospin Announce Strategic Partnership for the Global Distribution of CIL’s NMR Solvents

Cambridge Isotope Laboratories, Inc. is entering a global, strategic partnership with Bruker BioSpin for the distribution of CIL’s NMR solvents.

CIL News| Cambridge Isotope Laboratories
metabolic substrates, isotope labeling, SILAC Amino Acids, protein standards, SILAC, Metabolic Labeling, NMR Tubes, Nucleic Acid Synthesis, alpha keto acids, Cell-Free Protein Expression, deuterated compounds, biomolecular nor, stable isotope, Hyperpolarization, nuclear medicine isotopes, Stable Isotopes, protein NMR, Protein Reagents, Deuterium labeled compounds, minimal media, Heavy Isotopes, metabolic research, custom synthesis, mass spectrometry, list of stable isotopes, Quantitative Proteomics, Nuclear Medicine, Metabolomics, food testing, Solid State NMR, proteomics, Membrane Proteins, mass spectrometry isotopes, Nucleic Acid, NMR, Protein Expression, material testing, Peptide Synthesis
CIL and its people have been committed to high quality stable isotope labeled products, superior customer service, innovative new products and a breadth of product lines.